The Vanguard Group 13D and 13G filings for Arrowhead Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-04-10 2:03 pm Purchase |
2024-03-28 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
The Vanguard Group | 12,404,050 10.010% |
1,731,974 (+16.23%) |
Filing |
| 2024-02-13 4:58 pm Sale |
2023-12-29 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
The Vanguard Group | 10,672,076 9.930% |
-158,357 (-1.46%) |
Filing |
| 2023-06-09 2:15 pm Purchase |
2023-05-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
The Vanguard Group | 10,830,433 10.130% |
544,261 (+5.29%) |
Filing |
| 2023-02-09 11:07 am Purchase |
2022-12-30 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
The Vanguard Group | 10,286,172 9.700% |
646,029 (+6.70%) |
Filing |
| 2022-02-09 3:24 pm Purchase |
2021-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
The Vanguard Group | 9,640,143 9.220% |
358,592 (+3.86%) |
Filing |
| 2021-02-10 10:30 am Sale |
2020-12-31 | 13G | Arrowhead Pharmaceuticals, Inc. ARWR |
The Vanguard Group | 9,281,551 9.030% |
-515,956 (-5.27%) |
Filing |